Bleakley Financial Group LLC Makes New Investment in TG Therapeutics, Inc. $TGTX

Bleakley Financial Group LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 11,628 shares of the biopharmaceutical company’s stock, valued at approximately $386,000.

Other institutional investors have also made changes to their positions in the company. Danske Bank A S bought a new position in TG Therapeutics during the third quarter worth $25,000. Hantz Financial Services Inc. increased its stake in TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 560 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 573 shares during the last quarter. Truvestments Capital LLC raised its holdings in shares of TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,026 shares during the period. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth $52,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX opened at $54.87 on Friday. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The stock has a 50 day simple moving average of $47.75 and a 200-day simple moving average of $37.16. The company has a market cap of $8.40 billion, a PE ratio of 19.19, a P/E/G ratio of 1.38 and a beta of 1.60. TG Therapeutics, Inc. has a 12-month low of $25.28 and a 12-month high of $59.30.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The business had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. During the same period last year, the company earned $0.03 earnings per share. The business’s quarterly revenue was up 69.5% compared to the same quarter last year. On average, equities research analysts forecast that TG Therapeutics, Inc. will post 1.46 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TGTX. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a research note on Monday, June 22nd. Bank of America raised their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Finally, HC Wainwright upped their target price on TG Therapeutics from $70.00 to $77.00 and gave the company a “buy” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $53.33.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.